Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences is unprofitable, and its most important product faces new competition. But the new, just-launched version of its Cologuard test could spur top-line growth. The improved cancer ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 ... including a record number with Cologuard and Oncotype DX, growing total revenue 13% year over year ...

This approach contributed to strong growth in Cologuard test utilization among rescreen patients and within care gap programs during the third quarter. Exact Sciences received FDA approval for the ...

What's going on with Exact Sciences? Exact Sciences is best known for Cologuard, its at-home, non-invasive stool test for colorectal cancer. The company has helped screen millions of eligible ...

Equities are still in a bull run. The S&P 500 is up by 22% so far in 2024. Not every company has come along for the ride, though. Exact Sciences (NASDAQ: EXAS), a cancer-focused biotechnology ...